Australian Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Vita Life Sciences

Market Cap: AU$136.3m

A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.

Vitrafy Life Sciences

Market Cap: AU$79.8m

Engages in the research, development, and commercialization of cryopreservation solutions in Australia.

OncoSil Medical

Market Cap: AU$31.1m

A medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma.

Firebrick Pharma

Market Cap: AU$15.7m

Engages in the development and commercializing of formulations for the uses of povidone iodine in Australia, the United states and Singapore.

Avecho Biotechnology

Market Cap: AU$22.2m

A biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India.

Clinuvel Pharmaceuticals

Market Cap: AU$561.4m

A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

Immutep

Market Cap: AU$374.3m

A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.

Proteomics International Laboratories

Market Cap: AU$52.4m

Operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia.

Prescient Therapeutics

Market Cap: AU$44.2m

A clinical stage oncology company, develops drugs for the treatment of various cancers in Australia.

LTR Pharma

Market Cap: AU$122.2m

A clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.

Arovella Therapeutics

Market Cap: AU$116.1m

A biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally.

Argenica Therapeutics

Market Cap: AU$34.7m

A biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia.

Algorae Pharmaceuticals

Market Cap: AU$13.5m

A pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand.

Medical Developments International

Market Cap: AU$75.5m

Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally.

Syntara

Market Cap: AU$40.8m

Operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia.

Nyrada

Market Cap: AU$68.1m

A pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases.

Neuren Pharmaceuticals

Market Cap: AU$2.5b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

Hexima

Market Cap: AU$2.2m

Does not have significant operations.

Dimerix

Market Cap: AU$312.1m

A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.

Cleo Diagnostics

Market Cap: AU$47.5m

A biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia.

Biotron

Market Cap: AU$4.0m

A biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.

Invex Therapeutics

Market Cap: AU$12.0m

A biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.

Clarity Pharmaceuticals

Market Cap: AU$1.4b

A clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States.

Genetic Signatures

Market Cap: AU$60.2m

Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.

Patrys

Market Cap: AU$9.2m

Develops and commercializes antibody technologies for the treatment of cancer in Australia.

EZZ Life Science Holdings

Market Cap: AU$104.3m

Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia.

Trajan Group Holdings

Market Cap: AU$112.9m

Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.

Paradigm Biopharmaceuticals

Market Cap: AU$111.2m

Engages in the research and development of therapeutic products for human use in Australia.

PYC Therapeutics

Market Cap: AU$586.2m

A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.

Emyria

Market Cap: AU$39.2m

Engages in delivering and developing of treatments for mental health and select neurological conditions in Australia.

Neurizon Therapeutics

Market Cap: AU$64.0m

A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases.

Orthocell

Market Cap: AU$284.5m

A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally.

Tissue Repair

Market Cap: AU$16.6m

A clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia.

Amplia Therapeutics

Market Cap: AU$82.1m

A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.

Immuron

Market Cap: AU$20.4m

A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.

Island Pharmaceuticals

Market Cap: AU$102.8m

A drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America.